Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-16 of 16
Keywords: Everolimus
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2022) 112 (1): 34–42.
Published Online: 12 January 2021
... (everolimus or temozolomide). Advanced PanNET patients treated at our center from 1992 to 2013 were retrospectively reviewed. Patients received bolus 5-FU (400 mg/m 2 ), streptozocin (400 mg/m 2 ) (both IV, days 1–5), and doxorubicin (40 mg/m 2 IV, day 1) every 28 days. Overall response rate (ORR...
Journal Articles
Francesca Terracciano, Alessia Capone, Andrea Montori, Maria Rinzivillo, Stefano Partelli, Francesco Panzuto, Emanuela Pilozzi, Paolo Giorgio Arcidiacono, Claudio Sette, Gabriele Capurso
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (8): 739–751.
Published Online: 02 July 2020
... in pancreatic neuroendocrine neoplasms (PanNENs) underlies the introduction of the mTORC1 inhibitor everolimus as treatment of advanced progressive PanNENs. Although everolimus significantly increases progression-free survival, most patients acquire secondary resistance to the drug. This study aimed...
Journal Articles
Carine Mauro, Victor Hugo Fonseca de Jesus, Milton Barros, Frederico Perego Costa, Rui F. Weschenfelder, Nathalia D'Agustini, Martin Angel, Romina Luca, Jose Eduardo Nuñez, Juan Manuel O'Connor, Rachel P. Riechelmann
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (7): 631–638.
Published Online: 13 May 2020
... with neuroendocrine tumors (NET) treated with everolimus outside of clinical trials. We aimed to evaluate the frequency of and risk factors for opportunistic infections (Opl) or any serious infection in eligible patients. Methods: This was a retrospective multicenter study of a Latin American cohort of consecutive...
Journal Articles
Hiroyuki Okuyama, Masafumi Ikeda, Takuji Okusaka, Masayuki Furukawa, Shinichi Ohkawa, Ayumu Hosokawa, Yasushi Kojima, Hiroki Hara, Gou Murohisa, Kazuhiko Shioji, Akinori Asagi, Nobumasa Mizuno, Motohiro Kojima, Takeharu Yamanaka, Junji Furuse
Journal:
Neuroendocrinology
Neuroendocrinology (2020) 110 (11-12): 988–993.
Published Online: 02 January 2020
... as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established. Objectives: We evaluated the safety and efficacy of everolimus in patients with pancreatic NEC refractory or intolerant to platinum-containing chemotherapy...
Journal Articles
John K. Ramage, Pankaj Punia, Olusola Faluyi, Andrea Frilling, Tim Meyer, Ruby Saharan, Juan W. Valle
Journal:
Neuroendocrinology
Neuroendocrinology (2019) 108 (4): 317–327.
Published Online: 18 June 2019
... neuroendocrine neoplasms (PanNENs) treated with everolimus in routine clinical practice. Methods: In a prospective, non-interventional, multi-center study patients administered at least one 10 mg dose of everolimus were evaluated for change in HRQoL (EORTC QLQ-C30 Global Health Status scale) from baseline after...
Journal Articles
Emilio Bajetta, Laura Catena, Sara Pusceddu, Francesca Spada, Claudio Iannacone, Italo Sarno, Giandomenico Di Menna, Lorenzo Dottorini, Anna Maria Marte
Journal:
Neuroendocrinology
Neuroendocrinology (2018) 106 (4): 307–311.
Published Online: 26 July 2017
...Emilio Bajetta; Laura Catena; Sara Pusceddu; Francesca Spada; Claudio Iannacone; Italo Sarno; Giandomenico Di Menna; Lorenzo Dottorini; Anna Maria Marte Background: We previously presented data of this multicentric, phase II study showing that everolimus plus octreotide long-acting repeatable (LAR...
Journal Articles
Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiri Tomasek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili-Pacaud, Jeremie Lincy, Edward Wolin, Natsuko Okita, Steven K. Libutti, Do-Youn Oh, Matthew Kulke, Jonathan Strosberg, James C. Yao, Marianne E. Pavel, Nicola Fazio, for the RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group
Journal:
Neuroendocrinology
Neuroendocrinology (2018) 106 (3): 211–220.
Published Online: 24 May 2017
... E. Pavel; Nicola Fazio; for the RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group Purpose: The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 105 (4): 394–402.
Published Online: 01 April 2017
...Anna Angelousi; Kimberly Kamp; Maria Kaltsatou; Dermot O'Toole; Gregory Kaltsas; Wouter de Herder Objective: Alternating treatment with sunitinib and everolimus has been shown to be efficacious in renal cell carcinoma. However, no data currently exist for the role of alternate sequence...
Journal Articles
Marianne Pavel, Juan W. Valle, Barbro Eriksson, Anja Rinke, Martyn Caplin, Jie Chen, Frederico Costa, Jenny Falkerby, Nicola Fazio, Vera Gorbounova, Wouter de Herder, Matthew Kulke, Catherine Lombard-Bohas, Juan O'Connor, Halfdan Sorbye, Rocio Garcia-Carbonero, all other Antibes Consensus Conference participants
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 105 (3): 266–280.
Published Online: 29 March 2017
... with biotherapy. More recently, novel targeted drugs, such as the mammalian target of rapamycin inhibitor everolimus and the multiple tyrosine kinase inhibitor sunitinib, have been introduced in the management of NETs. Although targeted drugs are generally well tolerated, with most adverse events being of mild...
Journal Articles
Clemens Reuther, Vera Heinzle, Svenja Nölting, Sabine Herterich, Stefanie Hahner, Ensar Halilovic, Sébastien Jeay, Jens U. Wuerthner, Elke Tatjana Aristizabal Prada, Gerald Spöttl, Julian Maurer, Christoph J. Auernhammer
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 106 (1): 1–19.
Published Online: 21 November 2016
... < 0.01). In a Western blot analysis of GOT1 cells, NVP-CGM097 caused a dose-dependent increase in the expression of p53 and p21 tumor suppressor proteins and a decrease in phospho-Rb and E2F1. Experiments of co-incubation of NVP-CGM097 with 5-fluorouracil, temozolomide, or everolimus each showed additive...
Journal Articles
Helma Freitag, Friederike Christen, Florentine Lewens, Irina Grass, Franziska Briest, Sara Iwaszkiewicz, Britta Siegmund, Patricia Grabowski
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 105 (1): 90–104.
Published Online: 12 August 2016
..., and compared them with those of the established mTORC1 inhibitor everolimus. Methods: We treated BON, QGP-1, KRJ-I, and LCC-18 cell lines with increasing concentrations of the inhibitor PKI-587, and compared the results with those of everolimus and DMSO. We assessed the impact of the treatments on viability...
Journal Articles
Adrian Lee, David L. Chan, Matthew H. Wong, Bob T. Li, Sumit Lumba, Stephen J. Clarke, Jaswinder Samra, Nick Pavlakis
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 104 (3): 209–222.
Published Online: 16 April 2016
...-effects model, with studies pooled according to drug class and/or control arm for clinical homogeneity. Results: Fifteen RCT [SSA, n = 2; mammalian target of rapamycin (mTOR)/VEGF inhibitors, n = 4; IFN, n = 3; targeted therapy added to everolimus, n = 2, and other, n = 4] investigating 2,790 patients...
Journal Articles
Jerome Cros, Emilie Moati, Jerome Raffenne, Olivia Hentic, Magali Svrcek, Louis de Mestier, Emilie Sbidian, Nathalie Guedj, Pierre Bedossa, Valerie Paradis, Alain Sauvanet, Yves Panis, Philippe Ruszniewski, Anne Couvelard, Pascal Hammel
Journal:
Neuroendocrinology
Neuroendocrinology (2016) 103 (5): 495–499.
Published Online: 04 September 2015
... nucleotide polymorphism substituting a glycine for an arginine in codon 388 of the FGFR4 transmembrane domain may increase the proliferation of xenografted neuroendocrine cell lines and decrease their sensitivity to everolimus by modulating STAT3 signaling and the mTOR pathway. Aim: To evaluate...
Journal Articles
Lowell B. Anthony, Marianne E. Pavel, John D. Hainsworth, Larry K. Kvols, Scott Segal, Dieter Hörsch, Eric Van Cutsem, Kjell Öberg, James C. Yao
Journal:
Neuroendocrinology
Neuroendocrinology (2015) 102 (1-2): 18–25.
Published Online: 21 March 2015
...Lowell B. Anthony; Marianne E. Pavel; John D. Hainsworth; Larry K. Kvols; Scott Segal; Dieter Hörsch; Eric Van Cutsem; Kjell Öberg; James C. Yao Background/Aims: The phase III placebo-controlled RADIANT-2 trial investigated the efficacy of everolimus plus octreotide long-acting repeatable (LAR...
Journal Articles
Zsuzsanna Bago-Horvath, Wolfgang Sieghart, Michael Grusch, Andreas Lackner, Hubert Hayden, Christine Pirker, Oxana Komina, Józefa Węsierska-Gądek, Andrea Haitel, Martin Filipits, Walter Berger, Katharina Schmid
Journal:
Neuroendocrinology
Neuroendocrinology (2012) 96 (3): 228–237.
Published Online: 24 February 2012
... with clinicopathological parameters and patient survival. Cytotoxicity of mTOR inhibitor everolimus and EGFR inhibitor erlotinib alone and in combination was assessed using growth inhibition assay in NCI-H720 AC and SHP-77 LCNEC cells. Cell cycle phase distribution was determined by FACS. Apoptosis-associated activation...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2010) 92 (Suppl. 1): 28–34.
Published Online: 10 September 2010
... Everolimus Adrenal tumors include benign and malignant cortical tumors and benign and malignant pheochromocytomas [ 1 ]. The malignant adrenal tumors are aggressive tumors with a poor prognosis [ 2,3,4,5 ]. The surgical removal of the tumor represents the treatment of choice for both benign...